Pipeline Overview

Product Candidate Phase of Development Indication
HyperAcute® Immunotherapy Technology
HyperAcute Pancreas Phase 3 Adjuvant to standard-of-care in surgically-resected pancreatic cancer
HyperAcute Lung Phase 1/2 enrollment complete Advanced NSCLC
HyperAcute Melanoma Phase 2 enrollment complete(1) Advanced melanoma in combination with PEG-Intron
Additional HyperAcute cancer immunotherapies Lead optimization To be determined
IDO Pathway Inhibitor Technology
NLG8189 Phase 1B/2(2) 2nd-line metastatic solid tumors in combination with p53 adenovirus
  Phase 1B/2(2) 2nd-line metastatic solid tumors in combination with Taxotere
Additional IDO Pathway Inhibitor Candidates Lead optimization To be determined

(1) Investigator-initiated
(2) Co-sponsored by the National Cancer Institute

.